Aldeyra (ALDX) director granted multiple new stock option awards
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Aldeyra Therapeutics director Ben Bronstein received three stock option awards, each covering rights to buy common stock at an exercise price of $1.72 per share. The grants cover 4,977, 5,309, and 70,000 underlying shares, respectively, and are reported as compensation-related acquisitions rather than market purchases.
According to the filing, each option becomes exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided Bronstein continues serving on the Board of Directors and, for two grants, on the Nominating/Corporate Governance and Audit Committees through the applicable vesting dates. All options are scheduled to expire on June 8, 2036 if not exercised.
Positive
- None.
Negative
- None.
Insider Trade Summary
3 transactions reported
Mixed
3 txns
Insider
Bronstein Ben
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 70,000 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 5,309 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 4,977 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 70,000 shares (Direct, null)
Footnotes (1)
- Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Nominating/Corporate Governance Committee of the Board of Directors of the Issuer through the applicable vesting date. Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date.
Key Figures
Option grant size: 4,977 options
Option grant size: 5,309 options
Option grant size: 70,000 options
+2 more
5 metrics
Option grant size
4,977 options
Underlying Aldeyra common shares for one award
Option grant size
5,309 options
Underlying Aldeyra common shares for second award
Option grant size
70,000 options
Underlying Aldeyra common shares for largest award
Exercise price
$1.72 per share
Price to buy Aldeyra common stock under all options
Option expiration
June 8, 2036
Stated expiration date for each option award
Key Terms
Stock Option (Right to Buy), exercise price, expiration date, Nominating/Corporate Governance Committee, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 1.7200"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-06-08T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
Nominating/Corporate Governance Committee financial
"service as a member of the Nominating/Corporate Governance Committee"
A nominating/corporate governance committee is a small group of a company’s board members tasked with choosing and evaluating directors and setting the rules that guide how the board operates. Think of it as the board’s hiring and rule-making team: it shapes leadership, board makeup, independence and ethical standards, which in turn influence how well the company is overseen and how investor interests are protected.
Audit Committee financial
"service as a member of the Audit Committee of the Board of Directors"
A company's audit committee is a small group of board members who act like independent inspectors for the firm's finances, overseeing how financial reports are prepared, monitoring internal controls, and managing the relationship with external auditors. Investors care because a strong audit committee reduces the risk of accounting errors, fraud, or misleading statements, making financial statements more trustworthy and helping protect shareholder value.
FAQ
What did Aldeyra Therapeutics (ALDX) director Ben Bronstein report in this Form 4?
He reported receiving three stock option awards as compensation. The options cover 4,977, 5,309, and 70,000 shares of Aldeyra common stock, all at an exercise price of $1.72 per share and expiring on June 8, 2036, if unexercised.
Are Ben Bronstein’s Aldeyra (ALDX) option grants open-market purchases or compensation awards?
They are compensation-related awards, not open-market purchases. The filing classifies each transaction with code “A” as a grant or award, with a transaction price of $0.00 per option and a separate exercise price of $1.72 for buying Aldeyra common shares later.
What are the vesting terms of Ben Bronstein’s new Aldeyra (ALDX) stock options?
Each option becomes exercisable for 100% of the shares one year after the grant date. Vesting requires continuous service on the Board, and for two grants continued service on the Nominating/Corporate Governance Committee and Audit Committee through the applicable one-year vesting dates.
What is the exercise price and expiration date of the Aldeyra (ALDX) options granted to Ben Bronstein?
All three option awards have an exercise price of $1.72 per share. Each option is scheduled to expire on June 8, 2036, meaning Bronstein may exercise them any time after vesting and before that expiration date, subject to plan terms.